Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
TR1 – Notification of major interest in shares by Lanstead Capital
May 18, 2020
Click here for information
IMM RNS Form TR1 Lanstead 18 May 2020
←
Previous:
ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka
Next:
Notice of AGM and posting of Report & Accounts
→
